Retraction of: HOXD-AS1 Exerts Oncogenic Functions and Promotes Chemoresistance in Cisplatin-Resistant Cervical Cancer Cells by Chi et al. (doi: 10.1089/hum.2017.256).

Abstract

Human Gene TherapyVol. 33, No. 9-10 Retraction NoticeOpen AccessRetraction of: HOXD-AS1 Exerts Oncogenic Functions and Promotes Chemoresistance in Cisplatin-Resistant Cervical Cancer Cells by Chi et al. (doi: 10.1089/hum.2017.256)This article retracts the following:Retracted: HOXD-AS1 Exerts Oncogenic Functions and Promotes Chemoresistance in Cisplatin-Resistant Cervical Cancer CellsPublished Online:16 May 2022https://doi.org/10.1089/hum.2017.256.retractAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail Dr. Chi Chi, the lead author of the article entitled, “HOXD-AS1 Exerts Oncogenic Functions and Promotes Chemoresistance in Cisplatin-Resistant Cervical Cancer Cells” (by Chi Chi, Min Mao, Zongji Shen, Youguo Chen, Jie Chen, and Wenjie Hou, Hum Gene Ther 2018;29(12):1438–1448; doi: 10.1089/hum.2017.256) requested that their published article in Human Gene Therapy be officially retracted due to their recent inability to repeat the results of the experiments in the study.An email from Dr. Chi received by the editorial office read, “My co-authors and I recently repeated the experiments and found some differences compared to the previous study results, which drew our great attention. For the rigor of scientific research, we have to [retract] our manuscript and need more time to verify the final results. We [are] sorry for this decision…”After reviewing the circumstances and seeking all authors' agreement, the editorial leadership of the journal agreed to retract the article.Human Gene Therapy is committed to upholding the rigorous standards of scientific publishing and the veracity of the literature.FiguresReferencesRelatedDetailsRelated articlesRetracted: HOXD-AS1 Exerts Oncogenic Functions and Promotes Chemoresistance in Cisplatin-Resistant Cervical Cancer Cells13 Dec 2018Human Gene Therapy Volume 33Issue 9-10May 2022 InformationCopyright 2022, by Mary Ann Liebert, Inc., publishersTo cite this article:Retraction of: HOXD-AS1 Exerts Oncogenic Functions and Promotes Chemoresistance in Cisplatin-Resistant Cervical Cancer Cells by Chi et al. (doi: 10.1089/hum.2017.256).Human Gene Therapy.May 2022.572-572.http://doi.org/10.1089/hum.2017.256.retractcreative commons licensePublished in Volume: 33 Issue 9-10: May 16, 2022Online Ahead of Print:March 28, 2022PDF download